出版物・学会関連リソース

本ページでは、医療従事者の皆さまに向けたグローバルな学術情報交換を支援する、アステラスの科学的出版物および学会関連リソースを掲載しています。

アステラスが実施または支援する研究に基づく査読付き論文、学会抄録、ポスター、プレゼンテーション資料に加え、平易な言葉でまとめたサマリー、動画、インフォグラフィックス、データ開示資料などの関連コンテンツをご覧いただけます。

出版物

本サイトに掲載されている情報は、医療従事者のみを対象としています。一般の方を対象としたものではなく、医学的なアドバイスを提供するものではありません。医学的なアドバイスやご質問については、必ず適切な資格を有する医療従事者にご相談ください。

 

本サイトはグローバル向けのリソースであり、お住まいの国·地域には該当しない情報が含まれている可能性があることにご注意ください。掲載資料は科学的な情報交換を目的としたもので、開発中の化合物や未承認の適応に関するデータを含む場合があります。承認状況や販売状況は国によって異なりますので、詳細は各国の規制当局の情報をご確認ください。また、本サイトに掲載されている学会関連資料は査読を受けておりません。臨床上の判断を行う際には、査読済み文献や臨床ガイドラインなどと併せて慎重にご検討いただくことをお勧めします。

 

許可なく、本コンテンツを配布、複製、提示、その他の方法で共有することは禁止されています。すべての権利は著作権保有者に帰属します。

キーワードを入力するか、利用可能なフィルターを選択して検索を開始してください。複数の条件を組み合わせることで、結果を絞り込み、最も関連性の高い文献を素早く見つけることができます。

Please enter at least 3 character to search

Filters

Poster

Predictors of treatment (Tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES

Authors: Armstrong AJ, Petrylak DP, Shore ND, et al.
Poster #5093
American Society of Clinical Oncology (ASCO)
Chicago, IL, USA
May 29-Jun 2, 2026
Study: ARCHES / 9785-CL-0335

Poster

Outcomes with androgen-deprivation therapy (ADT) plus androgen receptor pathway inhibitors (ARPIs) in veterans with de novo metastatic castration-sensitive prostate cancer (mCSPC) who were elderly, frail, or had high comorbidity: A subgroup analysis of enzalutamide and high-volume disease

Authors: Schoen MW, Doherty JM, Touya M, et al.
Poster #5094
American Society of Clinical Oncology (ASCO)
Chicago, IL, USA
May 29-Jun 2, 2026
Disease State: mCSPC

Poster

Trial in progress: HIGHLIGHT 1—a randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy

Authors: Bouchard C, Miyazaki K, Tang CH, et al.
Poster #127a
American Society of Clinical Oncology (ASCO)
Chicago, IL, USA
May 29-Jun 2, 2026
Study: HIGHLIGHT 1 / 2693-CL-1303

Poster

EMBARK: Testosterone recovery to >250 ng/dL following treatment suspension

Authors: Freedland SJ, Tutrone RF, Saad F, et al.
Poster #183
American Society of Clinical Oncology (ASCO)
Chicago, IL, USA
May 29-Jun 2, 2026
Disease State: nmCSPC
Study: EMBARK / MDV3100-13

Journal Article | Secondary manuscript - HEOR

Patient-reported outcome data from a randomized phase II study (STARLIGHT) of fezolinetant in women in Japan with vasomotor symptoms associated with menopause

Authors: Takamatsu K, Miki T, Miyazaki K, Hashimoto A, Morga A, Wang X
Climacteric. 2026;
Study: 2693-CL-0206

Presentation

Avacincaptad pegol reduces progression of ellipsoid zone loss and degradation in eyes with the highest baseline ellipsoid zone burden

Authors: Sivaprasad S, Talcott KE, Amine R, et al.
Presentation #143
The Royal College of Ophthalmologists Annual Congress (RCO)
Manchester, UK
May 18-21, 2026
Study: GATHER1, GATHER2

Poster

Structural insights into avacincaptad pegol inhibition of C5 activation for the treatment of geographic atrophy secondary to age-related macular degeneration

Authors: Dinah C, Musada GR, Moreno-Leon L, et al.
The Royal College of Ophthalmologists Annual Congress (RCO)
Manchester, UK
May 18-21, 2026

Poster

Health state utilities associated with geographic atrophy secondary to dry age-related macular degeneration

Authors: Dinah C, Matza LS, Stewart KD, et al.
The Royal College of Ophthalmologists Annual Congress (RCO)
Manchester, UK
May 18-21, 2026
Study: 3021-MA-3629

Presentation

Structure‒function link of ellipsoid zone integrity and low-luminance deficit in avacincaptad pegol-treated eyes with geographic atrophy

Authors: Gale R, Downes R, Matar K, et al.
Presentation #200
The Royal College of Ophthalmologists Annual Congress (RCO)
Manchester, UK
May 18-21, 2026
Study: GATHER1, GATHER2

Poster

Enzalutamide versus apalutamide in metastatic castration-sensitive prostate cancer: A real-world study in a US urology database

Authors: Schoen MW, Touya M, El-Chaar N, et al.
Poster #26-1718
American Urological Association (AUA)
Washington, DC, USA
May 15-18, 2026
Study: 9785-MA-3506

Poster

Structure‒function link of ellipsoid zone integrity and low-luminance deficit in avacincaptad pegol-treated eyes with geographic atrophy

Authors: Matar K, Downes R, Amine R, et al.
Retina World Congress (RWC)
Fort Lauderdale, Florida, USA
May 14-17, 2026
Study: GATHER1, GATHER2

Journal Article

Reply to Singh and Srivastav’s letter to the editor re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. efficacy and safety of mirabegron in patients with overactive bladder and cardiovascular comorbidities: A-post hoc analysis of randomised trials. eur urol focus. in press. https://doi.org/10.1016/j.euf.2026.01.010

Authors: Lockefeer A, Schild A, Anaokar S, Fode M
Eur Urol Focus. 2026;
Study: FY22-6563

Poster

In vitro platform to assess responses of vascular endothelial cells and retinal pigment epithelial cells to complement deficiency and angiogenic signals

Authors: Yan J, Musada GR, Moreno-Leon L, Lombardi N, Khanna H
Poster #111 - 0141
Association for Research in Vision and Ophthalmology (ARVO)
Denver, Colorado, USA
May 3-7, 2026

Presentation

Subretinal transplantation of human stem cell-derived retinal pigment epithelium (ASP7317) for the treatment of advanced geographic atrophy: Preliminary phase 1b results

Authors: Hau VS, Leng T, Yonekawa Y, et al.
Presentation #5505
Association for Research in Vision and Ophthalmology (ARVO)
Denver, Colorado, USA
May 3-7, 2026
Study: 7317-CL-0003

Poster

Avacincaptad pegol for geographic atrophy: Pharmacokinetics and immunogenicity from the GATHER2 open-label extension

Authors: Desai A, Heier JS, Chichili GR, et al.
Poster #1788 - 0550
Association for Research in Vision and Ophthalmology (ARVO)
Denver, Colorado, USA
May 3-7, 2026
Study: ISEE2009

Poster

Epidemiology of stargardt disease (STGD) and macular dystrophies (MDs) expressing a STGD-like clinical presentation

Authors: Iannaccone A, Rovelt J, Haselkorn T, et al.
Poster #5025 - 0068
Association for Research in Vision and Ophthalmology (ARVO)
Denver, Colorado, USA
May 3-7, 2026

Poster

Treatment-seeking behavior in patients with geographic atrophy: Results from patient and caregiver interviews

Authors: Chan N, Smith CB, Rubinstein E, et al.
Poster #5260 - 0374
Association for Research in Vision and Ophthalmology (ARVO)
Denver, Colorado, USA
May 3-7, 2026
Study: ATLAS / 0485-CL-0001

Poster

Time-to-event analysis of driving eligibility maintenance following treatment with avacincaptad pegol in patients with geographic atrophy

Authors: Chang M, Sheth V, Danzig C, et al.
Poster #1777 - 0539
Association for Research in Vision and Ophthalmology (ARVO)
Denver, Colorado, USA
May 3-7, 2026
Study: GATHER1, GATHER2

Poster

Mechanism of complement C5 inhibition by avacincaptad pegol (ACP): Insights from ACP-C5 structure determination

Authors: Moreno-Leon L, Musada G, Sutton S, et al.
Poster #110 - 0140
Association for Research in Vision and Ophthalmology (ARVO)
Denver, Colorado, USA
May 3-7, 2026

Presentation

Avacincaptad pegol for geographic atrophy: 3.5-year results from the GATHER2 open-label extension trial

Authors: Kaiser PK, Khanani AM, Heier JS, et al.
Presentation #5959
Association for Research in Vision and Ophthalmology (ARVO)
Denver, Colorado, USA
May 3-7, 2026
Study: ISEE2009